Stock Screener App

無料 - Play StoreApp Store

インストールインストール

Dow:

Nasdaq:

S&P 500:

AZN

$186.657.02%12.25

アフターアワーズ： 186.35-0.30 -0.16%

Astrazeneca Plc (AZN)

Date: O: H: L: C: Vol:

Astrazeneca Plc (AZN) 最新ニュース

Pre-Markets in Red on Massive AI Spending Concerns - Zacks Investment Research

Pre-Markets Spooked on Questions Regarding AI, Oil Prices - Zacks Investment Research

AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth - Zacks Investment Research

Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise - Zacks Investment Research

2027 Could Finally Be the Year Cancer Is on the Ropes! - GlobeNewswire Inc.

MRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock Up - Zacks Investment Research

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer - GlobeNewswire Inc.

Onco360® Has Been Selected as a National Pharmacy Partner for ZEGFROVY® (sunvozertinib) - GlobeNewswire Inc.

REG - Niox Group PLC AstraZeneca PLC - Holding(s) in Company - TradingView

Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer - Benzinga

Is AstraZeneca’s Pipeline Fuel Enough to Spark a Post-Earnings Breakout on Oct. 30? - 24/7 Wall St.

AstraZeneca PLC : JP Morgan reaffirms its Buy rating - www.marketscreener.com

Breakfast News: Science Strikes Back at Cancer - The Motley Fool

AstraZeneca prepares to seek regulatory approval for new targeted cancer treatment - marketscreener.com

AstraZeneca highlights advances across cancer portfolio at ESMO 2026 - marketscreener.com

Hutchmed, AstraZeneca Say Potential Metastatic Non-Small Cell Lung Cancer Treatment Reduces Disease Progress - www.marketscreener.com

Double news for AstraZeneca at ESMO - marketscreener.com

AstraZeneca Imfinzi Cuts Death Risk by 58%, 42% in Lung, Bladder Cancer Studies - marketscreener.com

AstraZeneca advances new cancer drug - Breakingthenews.net

AstraZeneca stomach cancer drug doubles survival in late-stage trial (AZN:NYSE) - Seeking Alpha

Astra’s Experimental Stomach Cancer Drug Doubled Survival Time - Bloomberg.com

AstraZeneca: This Mighty Pharma Is Undervalued Ahead Of Q3 Earnings (NYSE:AZN) - Seeking Alpha

Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research

AstraZeneca PLC (AZN) Stock Forecasts - Yahoo Finance

Why Is AstraZeneca Stock Trading Higher Today? - AstraZeneca (NYSE:AZN) - Benzinga

AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy - Zacks Investment Research

AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy - Zacks Investment Research

AstraZeneca Launches Targeted Lung Cancer Drug In US After FDA Accelerated Approval - Yahoo Finance

Summit Expands Ivonescimab Development Into Biliary Tract Cancer - Zacks Investment Research

AstraZeneca, Abu Dhabi Biobank to Explore AI Platform for Disease Prediction - www.marketscreener.com

AstraZeneca bags another US indication for Ultomiris with IgAN approval - Yahoo Finance

P&G, Nestlé, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain Awards - Yahoo Finance

AstraZeneca Wins FDA Accelerated Approval for Ultomiris in Rare Kidney Disease - AskTraders.com

AstraZeneca says U.S. FDA approves rare kidney disease drug By Investing.com - Investing.com Nigeria

AstraZeneca says FDA approves drug for rare kidney disease in adults - www.marketscreener.com

AstraZeneca says FDA approves drug for rare kidney disease in adults - Reuters

Is AstraZeneca (AZN) Stock Cheap? - Yahoo Finance

Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.

AbbVie vs. AstraZeneca: Which Pharma Giant Has the Stronger Earnings Growth Story? - Yahoo Finance

AstraZeneca PLC : Gets a Buy rating from JP Morgan - marketscreener.com

Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? - Zacks Investment Research

Biotech ETF (BBH) Hits New 52-Week High - Zacks Investment Research

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? - The Motley Fool

Positive Results for an AstraZeneca and Amgen Product - marketscreener.com

Amgen, AstraZeneca Detail Phase III Data For Tezspire’s Likely Third Indication - Scrip

AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study - Benzinga

AstraZeneca (AZN) Adds Oncology Catalysts. Is the Pipeline Worth Its Earnings Multiple? - Yahoo Finance

AstraZeneca partners with Oracle for AI-driven clinical trials - Reuters

AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial - Reuters

GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research

AZNに類似

NVS$160.790.19%

AMGN$466.011.15%

GILD$170.683.06%

MRK$149.522.18%